跳至主要内容
临床试验/NCT00512187
NCT00512187已完成4 期

Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

Universita di Verona2 个研究点 分布在 1 个国家开始时间: 2005年11月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
试验地点
2
主要终点
Primary end point PASI 75 response

研究概览

简要总结

The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age,active but clinically stable plaque psoriasis involving at least 10 percent of the body surface area and a psoriasis area and severity index (PASI) score ≥10 and a body mass index ≥30.

排除标准

  • Other type of psoriasis (guttate, erythrodermic and pustular psoriasis)
  • Uncontrolled hypertension
  • Severe congestive heart failure
  • Renal and liver impairment
  • Active or chronic infections, including HIV, HBV and HCV infections, latent tuberculosis
  • Previous or active malignancies
  • Pregnancy and lactations
  • Previous treatment with cyclosporine
  • Phototherapy or any systemic or topical therapy for psoriasis within the previous 4 weeks before enrolment.

结局指标

主要结局

Primary end point PASI 75 response

时间窗: week 24

次要结局

  • secondary end point was % of body weight reduction(week 24)

研究者

发起方
Universita di Verona
申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Moderate Weight Loss Makes Obese Patients With... | 临床试验